The Eczema App

The Eczema App
An Eczema Focused Tracking App

Overview
A free and personalized on-the-go resource for people living with eczema.
Access comprehensive condition information, track your eczema flare-ups and get instant savings. The Eczema App is available on iPhone and iPod Touch devices.

Tracking Tool
Track your eczema flare-ups – and your progress.
Use the Tracker Tool in consultation with your healthcare professional to keep notes on your flare-ups and treatment. Create up to 3 profiles.

Reports
Get summary reports from the notes on the flare-ups you’ve tracked.
Review your flare-up history from the information entered in the tracking tool, and share your information with your healthcare professional.

Eczema Information
Get customized eczema information on the go.
Access comprehensive condition information including causes, symptoms and treatment options. View customized sections (Patients and Parents) with content tailored by age groups for the different needs of adults and parents with children living with eczema.

News
Keep up-to-date with eczema news.
News and articles by the National Eczema Association (NEA).

Desonate
Learn about Desonate (desonide) Gel, 0.05% - and get instant savings.
Desonate delivers relief from mild to moderate atopic dermatitis (eczema) symptoms for patients 3 months of age and older. Learn more about the benefits of Desonate, see before & after photos and get instant savings.

INDICATION AND USAGE

Desonate Gel is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

IMPORTANT SAFETY INFORMATION
Desonate is contraindicated in those with a history of hypersensitivity to any of the components of the preparation. Topical corticosteroids can produce reversible hypothalamic pituitary adrenal (HPA) axis suppression, Cushing’s syndrome and unmask latent diabetes. Systemic absorption may require evaluation for HPA axis suppression. Modify use should HPA axis suppression develop. Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption.

Pediatric patients may be more susceptible to systemic toxicity when treated with topical corticosteroids due to their larger skin surface-to-body mass ratios. Unless directed by a physician, do not use on the underarm or groin area of children. Do not use to treat diaper dermatitis. Use in children less than 3 months of age is not recommended.

Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids. The most common adverse reactions (incidence ≥ 1%) are headache, application site burning and rash. To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare at 1-866-463-3634 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Not for ophthalmic, oral or intravaginal use. As with other corticosteroids, therapy should be discontinued when control is achieved. Safety beyond 4 weeks has not been established.


Copyright © 2012 Bayer AG. All rights reserved.